Globally approved EGFR inhibitors: Insights into their syntheses, target kinases, biological activities, receptor interactions, and metabolism
Targeting the EGFR with small-molecule inhibitors is a confirmed valid strategy in cancer
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
therapy. Since the FDA approval of the first EGFR-TKI, erlotinib, great efforts have been …
Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade
Z Chen, T Shi, L Zhang, P Zhu, M Deng, C Huang, T Hu… - Cancer letters, 2016 - Elsevier
Multidrug resistance (MDR) is a serious phenomenon employed by cancer cells which
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …
hampers the success of cancer pharmacotherapy. One of the common mechanisms of MDR …
Preclinical comparison of the blood–brain barrier permeability of osimertinib with other EGFR TKIs
N Colclough, K Chen, P Johnström, N Strittmatter… - Clinical Cancer …, 2021 - AACR
Purpose: Osimertinib is a potent and selective EGFR tyrosine kinase inhibitor (EGFR-TKI) of
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …
both sensitizing and T790M resistance mutations. To treat metastatic brain disease, blood …
The modulation of ABC transporter-mediated multidrug resistance in cancer: a review of the past decade
ATP-binding cassette (ABC) transporters represent one of the largest and oldest families of
membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy …
membrane proteins in all extant phyla from prokaryotes to humans, which couple the energy …
Liquid biopsies to track trastuzumab resistance in metastatic HER2-positive gastric cancer
Objective To monitor trastuzumab resistance and determine the underlying mechanisms for
the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric …
the limited response rate and rapid emergence of resistance of HER2+ metastatic gastric …
[HTML][HTML] Regulation of multidrug resistance by microRNAs in anti-cancer therapy
X An, C Sarmiento, T Tan, H Zhu - Acta Pharmaceutica Sinica B, 2017 - Elsevier
Multidrug resistance (MDR) remains a major clinical obstacle to successful cancer treatment.
Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of …
Although diverse mechanisms of MDR have been well elucidated, such as dysregulation of …
[HTML][HTML] Cancer stem cells (CSCs), cervical CSCs and targeted therapies
R Huang, EK Rofstad - Oncotarget, 2017 - ncbi.nlm.nih.gov
Accumulating evidence has shown that cancer stem cells (CSCs) have a tumour-initiating
capacity and play crucial roles in tumour metastasis, relapse and chemo/radio-resistance …
capacity and play crucial roles in tumour metastasis, relapse and chemo/radio-resistance …
Tyrosine kinase inhibitors enhanced the efficacy of conventional chemotherapeutic agent in multidrug resistant cancer cells
S Wu, L Fu - Molecular cancer, 2018 - Springer
Multidrug resistance (MDR) triggered by ATP binding cassette (ABC) transporter such as
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
ABCB1, ABCC1, ABCG2 limited successful cancer chemotherapy. Unfortunately, no …
Dacomitinib antagonizes multidrug resistance (MDR) in cancer cells by inhibiting the efflux activity of ABCB1 and ABCG2 transporters
The development of multidrug resistance (MDR) to chemotherapy remains a major
challenge in the treatment of cancer. Numerous mechanisms have been recognized that …
challenge in the treatment of cancer. Numerous mechanisms have been recognized that …
Perspectives on drug repurposing to overcome cancer multidrug resistance mediated by ABCB1 and ABCG2
CP Wu, SH Hsiao, YS Wu - Drug Resistance Updates, 2023 - Elsevier
The overexpression of the human ATP-binding cassette (ABC) transporters in cancer cells is
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …
a common mechanism involved in developing multidrug resistance (MDR). Unfortunately …